Chart Industries, Inc. has announced an organisational realignment within its BioMedical division to “better position the company to capture future growth in the respiratory products industry.”

Under the restructuring, the US-based business will realign a portion of its current manufacturing and engineering operations and establish a centralised Respiratory Center-of-Excellence in its existing campus in Canton, Georgia.

As a result, Chart expects to consolidate a majority of its US respiratory operation and engineering activities into its Canton site by suspending the production and engineering of respiratory products at its Amherst location in New York.

“This transformation enables the company to improve collaboration and infrastructure utilisation to drive product innovation”

Earl Lawson, President of Chart BioMedical

It is understood that the strategic goal behind the move is to have all associated core engineering, manufacturing, sales and marketing resources located under one roof to better support growing demand in the respiratory products market.

Earl Lawson, President of Chart BioMedical, explained, “This transformation enables the company to improve collaboration and infrastructure utilisation to drive product innovation, efficiency, speed and quality.” 

“This realignment and our continued investment in respiratory solutions demonstrates our commitment to the industry and to improving the quality of life for millions of people suffering from COPD and other lung diseases.”